Managing RET Inhibitor Treatment-Related Adverse Events

Author(s):

Heather A. Wakelee, MD, FASCO,Jacob Sands, MD

Panelists discuss the common adverse effects for patients receiving selpercatinib or pralsetinib, strategies for managing these effects, and whether differences in the safety profiles of these drugs influence treatment choices for RET fusion–positive non–small cell lung cancer.

EP: 1.Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing

EP: 2.Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy

EP: 3.Testing Methodologies and Standards in Metastatic NSCLC

EP: 4.Practical Considerations in Metastatic NSCLC: Access and Timing of Testing

EP: 5.Clinical-Decision Making: When to Treat Advanced NSCLC Without Mutational Results

EP: 6.Initial Approach to Management of RET-Positive NSCLC

EP: 7.Patient and Therapy Considerations Guiding Initiation of Treatment in RET-Positive NSCLC

EP: 8.Considerations for First-Line Targeted Therapies in Metastatic RET-Positive NSCLC

EP: 9.Role of Immunotherapy and Chemotherapy in RET-Positive NSCLC

Now Viewing

EP: 10.Managing RET Inhibitor Treatment-Related Adverse Events

Dr Wakelee to Dr Sands: What adverse effects are common for patients receiving selpercatinib or pralsetinib?
How do you manage these adverse effects?
Are there any differences in safety profiles of these drugs that influence your treatment choice?
LIBRETTO-431 Trial
ARROW Trial
ARROW Trial Update Annals of Oncology, 2022
Dr Wakelee to Dr Sands: In what situations do you consider dose modifications of RET inhibitors? How often do you find this necessary in your practice?